Akari Therapeutics Appoints New CMO, Adds Director
Ticker: AKTX · Form: 8-K · Filed: Dec 16, 2024 · CIK: 1541157
Sentiment: neutral
Topics: leadership-change, board-appointment, executive-appointment
Related Tickers: AKTX
TL;DR
Akari Therapeutics beefs up leadership with a new CMO and a board member.
AI Summary
Akari Therapeutics Plc announced on December 12, 2024, the appointment of Dr. Robert J. Spiegel as Chief Medical Officer and the election of Ms. Jennifer L. McNeely to its Board of Directors. Dr. Spiegel brings extensive experience in drug development, and Ms. McNeely has a strong background in healthcare finance and operations.
Why It Matters
The appointment of a new Chief Medical Officer and the addition of a director with relevant expertise can signal a strategic shift or strengthening of leadership for the company's drug development and operational strategies.
Risk Assessment
Risk Level: medium — Changes in key leadership roles can introduce uncertainty regarding future strategy and execution, though the experience of the appointees may mitigate some risks.
Key Players & Entities
- Akari Therapeutics Plc (company) — The company filing the report.
- Dr. Robert J. Spiegel (person) — Newly appointed Chief Medical Officer.
- Ms. Jennifer L. McNeely (person) — Newly elected member of the Board of Directors.
- December 12, 2024 (date) — Date of the earliest event reported.
FAQ
What is the effective date of the reported events?
The earliest event reported is dated December 12, 2024.
Who has been appointed as the new Chief Medical Officer?
Dr. Robert J. Spiegel has been appointed as the new Chief Medical Officer.
Who has been elected to the Board of Directors?
Ms. Jennifer L. McNeely has been elected to the Board of Directors.
What is the company's primary business sector?
Akari Therapeutics Plc is in the Pharmaceutical Preparations sector, SIC code 2834.
What is the company's principal executive office address?
The company's business address is 22 Boston Wharf Road, FL 7, Boston, MA 02210.
Filing Stats: 647 words · 3 min read · ~2 pages · Grade level 10.6 · Accepted 2024-12-16 16:30:08
Key Financial Figures
- $0.0001 — tal Market Ordinary Shares, par value $0.0001 per share* *Trading, but only in conn
- $300,000 — be entitled to an annual base salary of $300,000 per year, with a target bonus percentag
Filing Documents
- aktx-20241212.htm (8-K) — 43KB
- 0000950170-24-136674.txt ( ) — 260KB
- aktx-20241212.xsd (EX-101.SCH) — 95KB
- aktx-20241212_htm.xml (XML) — 6KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Akari Therapeutics, Plc Date: December 16, 2024 By: /s/ Samir R. Patel, M.D. Samir R. Patel, M.D. Interim President and Chief Executive Officer